# Bulsara Bioworks

Source: https://onco.cc/companies/bulsara-bioworks/  
OnCo record `bulsara-bioworks` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Bulsara Bioworks is a 2025 start-up focused on precise p53-pathway activation for solid tumours.

## Summary

Bulsara Bioworks is a San Francisco start-up founded in 2025 and backed by Even One Ventures, focused on precise activation of the p53 pathway in solid tumours. The company describes a focused drug-development model built around p53 pathway biology, its work is preclinical, and it exhibited at BIO 2026. OnCo links it to TP53 as a target and to the p53, RB and cell-cycle checkpoint pathway. Whether the p53 pathway, long considered undruggable, can be reactivated selectively in tumour cells is the question its programme depends on, and no clinical data yet exist. The TP53 target page carries the history of earlier attempts.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Tags: early-stage
- HQ: San Francisco, CA
- Type: biotech
- Website: https://www.bulsarabio.com

## Sources

- BIO 2026 participant profile: https://convention.bio.org/participating-companies/bulsara-bioworks

## Connected records

- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [TP53](https://onco.cc/targets/tp53/)
- pathways: [p53 / RB / cell-cycle checkpoint](https://onco.cc/pathways/p53-cell-cycle/)

---
JSON: https://onco.cc/api/v1/entities/bulsara-bioworks.json